Plasma levels of propranolol were measured at intervals after the oral administration of 160 mg propranolol and 160 mg L.A. propranolol in ten subjects who received both drugs on separate occasions. Mean peak plasma concentration of propranolol occurred 2 h after propranolol and 10 h after the L.A. formulation; the peak concentration with the former was four times that with the latter. At 24 h the plasma level was significantly higher after L.A. propranolol. Observations were made in nine healthy volunteers who exercised before and at intervals after the oral administration of 160 mg propranolol and 160 mg L.A. propranolol. Propranolol produced a maximum reduction (27.84 ± 2.4%) in the exercise tachycardia at 3 h and L.A. propranolol a maximum reduction (22.00 ± 1.73%) at 6 h. The effects at 24 h were 9.24 ± 1.55 and 16.79 ± 2.16% respectively. Five subjects were given 160 mg propranolol as a single dose daily for 8 days and on a separate occasion similar treatment with L.A. propranolol. Subjects were exercised and blood samples were taken before and 3 h after each dose on days 1 to 5 and on day 8. The reduction in the exercise tachycardia 3 h after propranolol ranged from 33.0 to 36.9% and 24 h after propranolol from 12.2 to 20.8%. The corresponding values after L.A. propranolol were 26.8 and 31.4 (3 h values) and 20.4 and 25.0 (trough values). The trough plasma levels of propranolol during administration of propranolol ranged from 10.2 to 19.4 ng/ml and peak values from 202.2 to 245.0 ng/ml. The corresponding values after L.A. propranolol were 12.5 to 17.5 (trough values) and 18.4 to 50.0 (peak values) ng/ml. These observations show that the new long acting formulation of propranolol produces a significant reduction of an exercise tachycardia throughout a 24 h period without a very high initial effect during single and multiple dosing. This formulation should be suitable for once a day administration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429930 | PMC |
http://dx.doi.org/10.1111/j.1365-2125.1980.tb04793.x | DOI Listing |
Front Immunol
January 2025
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Introduction: Malignant pleural effusion (MPE) is associated with poor quality of life and mortality in patients with tumors. In clinical practice, we observed that patients with malignant pleural effusion (MPE) and concurrent heart disease exhibited a decrease in MPE volumes following treatment with β-receptor blockers for heart disease. Immunosuppressive tumor microenvironment was found to play a substantial role in the progression of MPE, and mainly attributed to tumor-associated macrophages (TAMs).
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Objective: Burns lead to systemic changes manifested by systemic disturbances in water-electrolyte balance and systemic metabolic and inflammatory responses. The hypermetabolic response after a burn injury relies on metabolic, hormonal, and inflammatory dysregulation mechanisms. This study aimed to provide a comprehensive bibliometric analysis of the burn metabolism research field, identifying key trends, influential contributors, and emerging research hotspots to inform future investigative efforts.
View Article and Find Full Text PDFJ Am Acad Dermatol
January 2025
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Division of Dermatology, The Hospital for Sick Children, Toronto, ON, Canada.
Cureus
December 2024
Department of Pediatrics, Toranomon Hospital, Tokyo, JPN.
Background: Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.
Materials And Methods: Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital.
Cureus
December 2024
Department of Pediatrics, The Jikei University School of Medicine, Tokyo, JPN.
Congenital intracranial hemangiomas are rare benign vascular tumors that develop before birth. Although various treatments, including surgery, steroids, interferon-α, thalidomide, bevacizumab, or propranolol, have been reported, no standard therapy has been established. We report the case of a neonate with congenital intracranial hemangioma and central nervous system symptoms requiring therapeutic intervention.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!